A long-awaited AlzForum's take on the news that ApoE4 homozygotism means in fact an AD pathology (though not necessarily dementia before death), https://www.alzforum.org/news/research-news/do-two-apoe4-alleles-always-mean-alzheimers

The comments-section gives a glimpse of some of the trenchlines regarding the treatment of dementia, but I guess the prevention-camp has only just been strirred up from their Sleeping Beauty's slumber.

I, as an example, still have only a 1 % measured risk of acquiring AD, according to some widely used screens, and no "preventable risk factors" except maybe age. Too bad, my genetic inheritance seems to have been enough to skew the Amyloid-Beta balance early on. Luckily, I was recruited to the aducanumab-study for four years (a precursor of lecanemab with more severe side-effects), and probably got some more years to be able to think things like these.

#alzheimer #research #medical #APOE4 #alzForum #dementia #ad #alzheimers #amyloid #lecanemab #aducanumab #prevention #cure

An expected news from Alzheimer therapies, https://www.alzforum.org/news/community-news/adieu-aduhelm-biogen-stops-marketing-antibody

A bit nostalgic, though, because I was one of the few whose cognition improved (relatively, i.e. compared to the control-group) during the years I got the antibody 10 mg / kg, enough for Biogen to apply for license.

It was a marvellous box-seat to observe pharmaceutical research with all it's intricacies, and live neurological expertise within an arm's reach was invaluable.

Here is the history of aducanumab, rest in pieces, https://www.alzforum.org/therapeutics/aduhelm

#alzheimers #aducanumab #aduhelm #biogen

"I think one of the reasons Leqembi was approved (and Lilly's donanemab is likely to be, this year) is that aducanumab was approved. I remain skeptical that these drugs will provide any real-world benefit, but I am not skeptical at all of the sales potentials for both of them."
#Alzheimer
#Leqembi
#aducanumab

https://www.science.org/content/blog-post/goodbye-aduhelm?s=09

Alzheimer’s disease is a devastating form of dementia affecting millions worldwide. A new drug, called aducanumab, has been approved by the FDA for treating Alzheimer’s. The drug works by clearing the toxic amyloid plaques that build up in the brain and cause memory loss. Many reports appeared last year disputing the amyloid hypothesis. The success of similar drugs in the past has been dismal.

#health #Alzheimers #aducanumab

https://www.womansworld.com/posts/health/alzheimers-cure

Ein Bericht von zwei Komitees des US-amerikanischen Repräsentantenhauses erhebt schwere Vorwürfe gegen die Zulassungsbehörde FDA im Zusammenhang mit dem umstrittenen Alzheimer-Medikament #Aducanumab.

https://gutepillen-schlechtepillen.de/aducanumab-bei-alzheimer-kritik-an-fda/

FDA approves #lecenemab via accelerated mechanism (same as #aducanumab):

https://www.statnews.com/2023/01/06/fda-approves-alzheimers-drug-leqembi-eisai/

CMS will still need to decide about Medicare coverage.

Eisai expected to seek full FDA approval based on additional cognitive outcomes data.

#dementia #alzheimers

"The 18-month investigation, initiated by two congressional committees after the F.D.A. approved the drug, also strongly criticized Biogen, Aduhelm’s manufacturer. Internal documents showed the company set “an unjustifiably high price” of $56,000 a year for Aduhelm because it wanted a history-making “blockbuster” to “establish Aduhelm as one of the top pharmaceutical launches of all time,” even though it knew the high price would burden Medicare and patients, the report found."

#Aduhelm #MonoclonalAntibody #Alzheimer #AlzheimersDisease #Aducanumab

https://www.nytimes.com/2022/12/29/health/alzheimers-drug-aduhelm-biogen.html?action=click&module=Well&pgtype=Homepage&section=Health